Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

November 8, 2022

https://www.globenewswire.com/news-release/2022/11/08/2550755/0/en/Fulcrum-Therapeutics-Announces-Recent-Business-Highlights-and-Third-Quarter-2022-Financial-Results.html

― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) ―

― Presented 96-week data from the Phase 2 ReDUX4 trial open label extension (OLE) study at World Muscle Society (WMS) conference ―

Read more at globenewswire.com

Related news for (FULC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.